Keros Therapeutics
KROS
126 hedge funds and large institutions have $948M invested in Keros Therapeutics in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 44 increasing their positions, 31 reducing their positions, and 14 closing their positions.
113,650% more call options, than puts
Call options by funds: $4.55M | Put options by funds: $4K
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
54% more capital invested
Capital invested by funds: $617M → $948M (+$331M)
42% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 31
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
12% more funds holding
Funds holding: 113 → 126 (+13)
1.51% more ownership
Funds ownership: 70.18% → 71.7% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$28.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$20M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$12.3M |
| 5 |
Alkeon Capital Management
New York
|
+$8.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$10.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$9.35M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.62M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$6.81M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.33M |
KROS Hedge Fund Activity: Q4 2022 in Review
126 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q4 2022, worth a combined $948M — up 54% from $617M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KROS positions and 14 closed out — a net gain of 15 holders — while 44 added to existing stakes and 31 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $28.6M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $10.3M sold.
- 126 institutional investors held Keros Therapeutics (KROS) as of Q4 2022, up from 113 in Q3 2022.
- Funds reported $948M of Keros Therapeutics stock for Q4 2022, up 54% quarter-over-quarter.
- 29 funds opened new Keros Therapeutics positions in Q4 2022 and 14 closed out, a net change of +15 holders.
- The largest Keros Therapeutics buyer in Q4 2022 was T. Rowe Price Associates, an estimated $28.6M added.
- The largest Keros Therapeutics seller in Q4 2022 was Fairmount Funds Management, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2022.